Climate change has been an increasingly hot topic (pun intended) in recent years, yet its direction isn’t always clear. Different world leaders take different stances and at times there is an unclear balance between the actions of governments, regulators and investor groups.
Chris Dodwell, Head of Policy and Advocacy at Impax Asset Management, helps us understand what to expect from COP30*, but more importantly how we can expect real world change to play out, and who plays the most critical role in this fight. He gives us reasons for optimism, highlights key innovations and explains why tackling climate change naturally aligns with broader business planning.
*COP30 is the 30th annual climate conference (“Conference of the Parties”), where world leaders get together to discuss ambitions, commitments and plans to tackle climate change in the future.
All content for Investment Uncut is the property of Lane Clark & Peacock and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Climate change has been an increasingly hot topic (pun intended) in recent years, yet its direction isn’t always clear. Different world leaders take different stances and at times there is an unclear balance between the actions of governments, regulators and investor groups.
Chris Dodwell, Head of Policy and Advocacy at Impax Asset Management, helps us understand what to expect from COP30*, but more importantly how we can expect real world change to play out, and who plays the most critical role in this fight. He gives us reasons for optimism, highlights key innovations and explains why tackling climate change naturally aligns with broader business planning.
*COP30 is the 30th annual climate conference (“Conference of the Parties”), where world leaders get together to discuss ambitions, commitments and plans to tackle climate change in the future.
S7 Ep.1: Kevin Patterson: Are pharma’s short-term pains a long-term opportunity?
Investment Uncut
26 minutes 43 seconds
1 month ago
S7 Ep.1: Kevin Patterson: Are pharma’s short-term pains a long-term opportunity?
Would you put pharmaceuticals on your buy list today? The sector is under pressure: revenues from COVID products are collapsing, the US administration is pushing for lower drug prices, and major players are cutting jobs amid rising competition.
Yet could this turbulence mark a compelling entry point for long-term investors? Kevin Patterson, US Access Solutions lead in LCP’s Health Analytics practice (based in our recently opened US office!), joins us to unpack what the current pain really means, who might win or lose, and where the most exciting opportunities lie.
Investment Uncut
Climate change has been an increasingly hot topic (pun intended) in recent years, yet its direction isn’t always clear. Different world leaders take different stances and at times there is an unclear balance between the actions of governments, regulators and investor groups.
Chris Dodwell, Head of Policy and Advocacy at Impax Asset Management, helps us understand what to expect from COP30*, but more importantly how we can expect real world change to play out, and who plays the most critical role in this fight. He gives us reasons for optimism, highlights key innovations and explains why tackling climate change naturally aligns with broader business planning.
*COP30 is the 30th annual climate conference (“Conference of the Parties”), where world leaders get together to discuss ambitions, commitments and plans to tackle climate change in the future.
